Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.
about
Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sexSex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3Explaining human recreational use of 'pesticides': The neurotoxin regulation model of substance use vs. the hijack model and implications for age and sex differences in drug consumption.Sex differences in drug disposition.Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combinatPharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus.The missing linkage: what pharmacogenetic associations are left to find in CYP3A?Gender differences in antidepressant drug response.Zolpidem for insomnia.Infant spinal anesthesia: Do girls need a larger dose of local anesthetic?Sex differences in transplantation.How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver.Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration.In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.
P2860
Q33451969-BA410B0C-6020-46D0-8B7D-650B87EAEEBEQ33683890-A65CA255-4805-44F8-819D-4B1F9AD02DCDQ33710324-6206EAEF-C1C6-45B6-9F29-3C287D4E2730Q34383507-1FF212B1-B0D7-4295-A94F-D7D705235EF1Q34635175-6D77AA77-A51B-4D46-9C3D-D23D4A7B409AQ35960735-E0142017-53D0-493B-B2C3-CA99F0F10926Q36693706-058D4C31-24A5-4019-BFE7-028BF888853AQ37646778-FC2415FD-59F4-4201-934F-0A7C0343EFC4Q37806757-4F6342E0-BAD4-49EE-B4D8-6CCAEF39B6CFQ37994346-90011EA5-1FCE-4615-9E6B-C4EB706EE742Q38620848-0DA0A20B-B200-49B7-8C85-00853EB037C5Q38750337-FA48B417-41CB-4F19-B6D4-8446CD023A80Q38994958-6ED2CD52-EECD-4A96-8792-51F15B9C7CA8Q41328717-3153F641-77C9-42D2-9AF3-5C7E0767BB1DQ42931493-8D052B01-5557-4B97-BA48-15CF5A10113DQ43046014-6AAFDAD1-A165-48B3-9B6B-CA2BF69A78D7Q45720916-DEFE5A83-694A-4A5B-8744-888D81A00D4EQ47917564-2B515B04-493E-483C-9620-0F7242879B3CQ48144743-68FB9F5F-584B-4E4D-90F0-5EBCD93127DEQ48247827-EE3FA950-B3C1-42BE-A37A-0ECAB1E3569CQ50072074-D5674611-B7EC-4CD2-AF42-FC3F5820BB9BQ51104966-AA7FA7E0-0687-45F1-A14D-841316DFED8F
P2860
Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@en
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@nl
type
label
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@en
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@nl
prefLabel
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@en
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@nl
P2860
P356
P1476
Gender has a small but statist ...... ance of CYP3A substrate drugs.
@en
P2093
David J Greenblatt
Lisa L von Moltke
P2860
P304
P356
10.1177/0091270008323754
P577
2008-08-29T00:00:00Z